Back to Search
Start Over
C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy.
- Source :
-
Scientific reports [Sci Rep] 2024 Jun 14; Vol. 14 (1), pp. 13765. Date of Electronic Publication: 2024 Jun 14. - Publication Year :
- 2024
-
Abstract
- To evaluate the prognostic value of biomarkers from peripheral blood obtained as routine laboratory assessment for overall survival in a cohort of stage III non-small cell lung cancer (NSCLC) patients treated with definitive radiochemotherapy at a high-volume cancer center. Seven blood biomarkers from 160 patients treated with definitive radiochemotherapy for stage III NSCLC were analyzed throughout the course treatment. Parameters were preselected using univariable and multivariable proportional hazards analysis and were assessed for internal validity using leave-one-out cross validation. Cross validated classifiers including biomarkers in addition to important clinical parameters were compared with classifiers containing the clinical parameters alone. An increased C-reactive protein (CRP) value in the final week of radiotherapy was found as a prognostic factor for overall survival, both as a continuous (HR 1.099 (1.038-1.164), p < 0.0012) as well as categorical variable splitting data at the median value of 1.2 mg/dl (HR 2.214 (1.388-3.531), p < 0.0008). In the multivariable analysis, the CRP value-maintained significance with an HR of 1.105 (1.040-1.173) and p-value of 0.0012. The cross validated classifier using CRP at the end of radiotherapy in addition to clinical parameters separated equally sized high and low risk groups more distinctly than a classifier containing the clinical parameters alone (HR = 2.786 (95% CI 1.686-4.605) vs. HR = 2.287 (95% CI 1.407-3.718)). Thus, the CRP value at the end of radiation therapy has successfully passed the crucial cross-validation test. The presented data on CRP levels suggests that inflammatory markers may become increasingly important during definitive radiochemotherapy, particularly with the growing utilization of immunotherapy as a consolidation therapy for stage III NSCLC.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Female
Male
Aged
Middle Aged
Prognosis
Adult
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung therapy
Carcinoma, Non-Small-Cell Lung blood
Carcinoma, Non-Small-Cell Lung pathology
Carcinoma, Non-Small-Cell Lung mortality
Carcinoma, Non-Small-Cell Lung radiotherapy
C-Reactive Protein metabolism
C-Reactive Protein analysis
Chemoradiotherapy
Lung Neoplasms therapy
Lung Neoplasms blood
Lung Neoplasms pathology
Lung Neoplasms mortality
Lung Neoplasms radiotherapy
Biomarkers, Tumor blood
Neoplasm Staging
Subjects
Details
- Language :
- English
- ISSN :
- 2045-2322
- Volume :
- 14
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Scientific reports
- Publication Type :
- Academic Journal
- Accession number :
- 38877146
- Full Text :
- https://doi.org/10.1038/s41598-024-64302-2